|
||
| |||||||
GHENT, Belgium, August 18, 2005 – Ablynx, a pioneer in the discovery and development of Nanobodies™, a novel class of antibody-derived therapeutic proteins, is pleased to announce the appointment of Dr Hennie Hoogenboom as Chief Scientific Officer. Dr Hoogenboom brings nearly 20 years of experience in antibody discovery and engineering. During his career he has led numerous research initiatives involving the discovery of recombinant antibodies and other proteins for therapy in the fields of oncology and inflammation. Previous positions include Senior Vice President Discovery of Dyax Corp, founder of Target Quest BV, associate professor at the University of Maastricht and group leader at Cambridge Antibody Technology Ltd. Dr Hoogenboom has co-authored over 100 scientific articles, reviews and book chapters, and is an inventor on more than 20 patent families. He holds a PhD in antibody engineering and worked as a postdoctoral fellow with Sir Gregory Winter at the MRC, where he co-invented phage display technology for the isolation and engineering of human antibodies. Welcoming Dr Hoogenboom as the new CSO, Dr Mark Vaeck, CEO of Ablynx said: “Hennie has broad experience and a successful track record in developing and applying therapeutic antibody platforms. I look forward to him making a major contribution to our continued success in the discovery and development of Nanobody™ based therapeutics and to help build Ablynx as a leading biopharmaceutical company.” Commenting on his appointment, Dr Hoogenboom said: “I am very impressed with the potential of Ablynx’s Nanobodies™ which combine the advantages of small molecule drugs with those of conventional antibodies. I am excited by the opportunity of heading the high-quality scientific team at Ablynx, of working with its leading academic collaborators worldwide and to applying the Company’s powerful drug discovery engine to build a solid drug development pipeline”. - Ends - About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies™, a novel class of antibody-derived therapeutic proteins, for a range of serious human diseases. Because of their small size, unique structure and unparalleled stability, Nanobodies™ combine the advantages of conventional antibodies with key features of small-molecule drugs. Ablynx has an unrivalled patent portfolio in the field of single domain antibodies with granted composition of matter claims both in the USA and Europe. Headquartered in Ghent, Belgium, Ablynx has raised over €33 million (over US$40 million) from a strong investor consortium including Abingworth Management (UK), Alta Partners (USA), Biotech Fund Flanders (Belgium), Gilde Investment Management (The Netherlands), GIMV (Belgium) and Sofinnova Partners (France). For further information please visit the website at www.ablynx.com ### Contacts
|
| |||||||||||||||
| ||||||||
